NervGen Pharma Corp.

NervGen Pharma Corp.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, NervGen Pharma Corp. has 106.41M shares outstanding.

As of June 30, 2026, NervGen Pharma Corp. maintains a current ratio of 1.23, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -115.68, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 10.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, NervGen Pharma Corp.'s stock has declined approximately 48.00% over the past 52 weeks. The 50-day moving average sits at 3.33, while the 200-day moving average is 2.80.

Over the twelve months ended June 30, 2026, NervGen Pharma Corp. generated - - in revenue and converted that into -38.21M in net income, yielding earnings per share of -0.47. EBITDA reached -19.89M, while operating income came in at -19.92M.

These figures are as of June 30, 2026. Total book value stands at 10.66M, with working capital of 10.42M providing operational flexibility.

NervGen Pharma Corp. produced -15.82M in operating cash flow over the twelve months ended June 30, 2026.